You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

 

CME / ABIM MOC / CE

Do Investigator Ties With Pharma Influence Trial Results?

  • Authors: News Author: Marcia Frellick; CME Author: Charles P. Vega, MD
  • CME / ABIM MOC / CE Released: 2/24/2017
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 2/24/2018
Start Activity


Target Audience and Goal Statement

This article is intended for primary care clinicians, nurses, pharmacists, and other clinicians who use medical literature to advance patient care.

The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.

Upon completion of this activity, participants will be able to:

  1. Evaluate the effects of industry sponsorship on study results
  2. Assess whether financial ties to industry by lead authors of randomized drug trials may affect the rate of positive study findings


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Author(s)

  • Marcia Frellick

    Freelance writer, Medscape

    Disclosures

    Disclosure: Marcia Frellick has disclosed no relevant financial relationships.

Editor(s)

  • Robert Morris, PharmD

    Associate CME Clinical Director, Medscape, LLC

    Disclosures

    Disclosure: Robert Morris, PharmD, has disclosed no relevant financial relationships.

CME Author(s)

  • Charles P. Vega, MD

    Health Sciences Clinical Professor of Family Medicine, University of California, Irvine, School of Medicine, Irvine, California

    Disclosures

    Disclosure: Charles P. Vega, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Allergan, Inc.; McNeil Consumer Healthcare
    Served as a speaker or a member of a speakers bureau for: Shire

CME Reviewer/Nurse Planner

  • Amy Bernard, MS, BSN, RN-BC

    Lead Nurse Planner, Medscape, LLC

    Disclosures

    Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.


Accreditation Statements


Medscape, LLC is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    This Enduring Material activity, Medscape Education Clinical Briefs, has been reviewed and is acceptable for credit by the American Academy of Family Physicians. Term of approval begins 9/1/2016. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Approved for 0.25 AAFP Prescribed credits.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    AAFP Accreditation Questions

    Contact This Provider

    For Nurses

  • Awarded 0.25 contact hour(s) of continuing nursing education for RNs and APNs; none of these credits is in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number 0461-0000-17-031-H04-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Do Investigator Ties With Pharma Influence Trial Results?

Authors: News Author: Marcia Frellick; CME Author: Charles P. Vega, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME / ABIM MOC / CE Released: 2/24/2017

Valid for credit through: 2/24/2018

processing....

Clinical Context

Research is critical to establish the efficacy and safety of medications, and randomized controlled trials represent the reference standard for interventional research. However, these studies are complex and expensive. Many such trials require financial support from the maker of the drug being studied, which introduces a substantial risk for bias.

Lundh and colleagues evaluated this risk in a meta-analysis published in the December 12, 2012, issue of the Cochrane Database of Systematic Reviews.[1] A total of 48 studies were included in the systematic review, and research sponsored by industry was more likely than nonsponsored research to have favorable outcomes for benefits, harms, and overall conclusions. Only 2 studies reported on device research only, and there was no significant higher rate of positive results in drug maker-supported studies of medical devices.

In general, industry-sponsored research did not include differences in methodology compared with nonsponsored research. In fact, industry-sponsored research had a lower risk for bias from blinding. The bias in industry-sponsored research was more likely to be found in interpretation of the study data; such research was slightly less likely to feature agreement between data and the conclusions of research.

This meta-analysis failed to account for compensation of the study authors themselves, and the current research by Ahn and colleagues fills this gap.

Study Synopsis and Perspective

Drug effectiveness trials authored by principal investigators who have financial ties to drug makers are more likely than other trials to report favorable results, according to a study published online January 17 in the BMJ.[2]

Previous studies have shown that industry-funded trials are more likely to be positive than those without industry funding, but these new data suggest that the likelihood of positive results increases when a principal investigator has industry ties, even after controlling for funding sources.

Specifically, trials run by primary investigators with industry ties were more than 3 times more likely to report positive results than were trials led by investigators without such ties. This result was obtained after adjustment for funding source, sample size, study phase, and design and outcome measures (odds ratio, 3.37; 95% confidence interval, 1.43-7.9), according to the study by Rosa Ahn, an MD/MPH student at Oregon Health and Science University in Portland, and colleagues.

The authors reviewed 195 randomized controlled trials published in 2013. They focused on drug effectiveness trials because of their direct effect on practices and healthcare costs.

More Than Half Had Financial Ties

Overall, 58% of principal investigators had financial ties to the drug industry in the form of travel expenses, honorariums, consultant fees, or stock ownership.

Among positive studies, the prevalence of a financial relationship between the principal investigators and the funder was 76% (103/136). Among negative studies, the prevalence was 49% (29/59).

US authors were more likely to have financial ties than were authors from other countries (70% vs 49%; P <.001).

Of the categories of ties that principal investigators reported, the most common was advisor/consultant fees, reported by 39% of principal investigators, followed by speakers' fees and unspecified ties (both 20%) and honorariums and employee relationships (13% each).

"These findings may be suggestive of bias in the evidence base," the authors write.

One strategy for reducing the potential bias is to require publishing of datasets, the authors write. The International Committee of Medical Journal Editors recently proposed that publication of datasets should be a requirement for journal publication, as reported by Medscape Medical News.[3]

"This requirement is increasingly common in other fields of inquiry such as economics," Ahn and colleagues note.

They also suggest it may be time to bring back independent statistical analysis of major randomized controlled trials, a practice largely replaced by transparency measures.

The authors say that among the reasons for the association between financial ties and positive outcomes may be that negative industry-funded studies may be less likely to get published than the positive ones. Also, single-site randomized controlled trials may not draw the interest of journals.

It could also be that the relationship affects the design of the study and its analytical approach, they say.

The authors acknowledge that the study is observational and cannot prove causation; however, they say, "more thought needs to be given to the roles that investigators, policy makers, and journal editors can play in ensuring the credibility of the evidence base."

Company's True Role Key

In an accompanying editorial,[4] Andreas Lundh, MD, from the Center for Evidence-based Medicine at Odense University Hospital in Denmark and University of Southern Denmark in Odense, and Lisa Bero, PhD, professor in the Charles Perkins Centre and Faculty of Pharmacy at the University of Sydney in Sydney, Australia, said it is important to know the company's true role in the study.

Some industry-linked trials are authored by opinion leaders "who act as window dressing" to add scientific credibility, but such trials are usually influenced by companies with little author input, they say.

A possible reason for more positive results, they say, is that companies may have a role in the design, such as the population used and comparators. Using an inferior dose of a comparison drug or changing the way outcomes are coded could favor the company's drug, for instance, they write.

"Although journals increasingly require authors to disclose what role a sponsor had in the design, conduct, or publication of a trial, to our knowledge no journals ask authors whether their financial relationships influenced the design, conduct, or publication of a trial," the editorialists write.

Journal editors could also reject work by authors who will not share data and penalize those who do not fully disclose financial relationships.

"Trials with industry funding or authors with financial ties should be interpreted with caution until all relevant information is fully disclosed and easily accessible," they conclude.

This project was not directly supported by any research funds. One coauthor has received support from the National Institutes of Health and Veterans Affairs Health Services Research and Development Service. Another coauthor's work on this article was supported by a Cancer Center Support Grant from the National Cancer Institute to Memorial Sloan Kettering Cancer Center. Dr Lundh is a member of the Danish organization Physicians without Sponsor, which seeks to promote independence from commercial influence in clinical work, research, and education. The other authors and editorialist have disclosed no relevant financial relationships.

BMJ. Published online January 17, 2017.

Study Highlights

  • Researchers evaluated randomized controlled trials published during 2013. All included studies evaluated the efficacy of drug interventions, and meta-analyses and other studies that did not include primary data were excluded from study evaluation, as was research without a clear funding source.
  • A study was considered to have positive results if the evidence from the research supported the hypothesis.
  • Researchers evaluated financial ties to the drug maker among the studies' principal investigators, first as stated in the study itself and then in an Internet search.
  • The main study outcome was the association between financial ties to the drug maker and the rate of trials with positive outcomes.
  • 190 trials comprising 195 studies were included in the final study analysis. Most studies were phase 3 trials, and 69% were funded by industry. 38% of first authors were based in the United States. The most frequently represented medical specialties among these authors were cardiology, oncology, and infectious diseases.
  • 50% of first authors self-reported a financial tie to the study's drug maker, and 47% denied any such association. The study investigators found that another 8% of first authors had a financial tie to the study's drug maker in their independent analysis.
  • The most common forms of compensation were advisor/consultancy payments, speakers' fees, honoraria, and employee relationships.
  • Researchers in the United States were more likely to have financial ties compared with authors in other countries.
  • The overall prevalence of financial ties was 76% in positive trials vs 49% in negative trials.
  • After adjustment for the source of study funding, the odds ratio for a positive trial associated with a sponsored first author was 3.57 (95% confidence interval, 1.7-7.7).
  • However, the researchers found no association between industry funding of research and the rate of positive results.
  • Secondary analyses based on the type of study, physician specialty, or primary outcome failed to alter the current study's main conclusion.

Clinical Implications

  • A previous systematic review by Lundh and colleagues found that research sponsored by industry was more likely than nonsponsored research to have favorable outcomes for benefits, harms, and overall conclusions. Sponsored research was more likely to draw conclusions unsupported by study data.
  • The current study by Ahn and colleagues suggests that studies in which the first author receives some form of compensation from the drug maker are more likely to include positive results.
  • Implications for the Healthcare Team: A torrent of clinical data is available on a daily basis; therefore, keeping track of all of these data and practicing some healthy skepticism toward the results are daunting tasks. The healthcare team may help by using solid medical evidence to construct algorithms that promote evidence-based care at the local level.

CME Test